Table 2. .
Patient and treatment characteristics
| Characteristics |
Single or oligo-metastasis
(n = 29) |
Oligoprogression
(n = 3) |
Dominant areas of progression
(n = 6) |
| Age (range) (years) | 55 (36–75) | 59 (53–62) | 67 (59–75) |
| Sex | |||
| Male | 13 (54%) | 1 (33%) | 6 (100%) |
| Female | 11 (46%) | 2 (67%) | 0 (0%) |
| Primary cancer | |||
| Non-small cell lung cancer | 8 (33%) | 1 (33%) | 3 (50%) |
| Breast cancer | 6 (25%) | 2 (67%) | 0 (0%) |
| Others a | 10 (42%) | 0 (0%) | 3 (50%) |
| Symptom (pain) | |||
| Yes | 7 (24%) | 3 (100%) | 5 (83%) |
| No | 22 (76%) | 0 (0%) | 1 (17%) |
| Systemic treatment | |||
| Yes | 21 (88%) | 3 (100%) | 3 (50%) |
| No | 3 (13%) | 0 (0%) | 3 (50%) |
| Diagnostic image at diagnosis | |||
| CT | 100 (100%) | 100 (100%) | 100 (100%) |
| PET | 24 (83%) | 2 (67%) | 2 (33%) |
| MRI | 13 (45%) | 1 (33%) | 3 (50%) |
| Bone scintigraphy | 25 (86%) | 3 (100%) | 4 (67%) |
| Diagnostic image at follow-up | |||
| CT | 27 (93%) | 3 (100%) | 5 (83%) |
| PET | 6 (21%) | 0 (0%) | 1 (17%) |
| MRI | 7 (24%) | 0 (0%) | 0 |
| Bone scintigraphy | 23 (79%) | 3 (100%) | 3 (50%) |
| Treated site | |||
| Pelvis | 18 (62%) | 3 (100%) | 4 (67%) |
| Femur | 3 (10%) | 0 (0%) | 2 (67%) |
| Rib | 5 (17%) | 0 (0%) | 0 (0%) |
| Scapular | 1 (3%) | 0 (0%) | 0 (0%) |
| Skull | 1 (3%) | 0 (0%) | 0 (0%) |
| Sternum | 1 (3%) | 0 (0%) | 0 (0%) |
| Metastatic tumor type | |||
| Lytic | 20 (87%) | 0 (0%) | 5 (83%) |
| Sclerotic | 0 (0%) | 0 (0%) | 0 (0%) |
| Mixed | 3 (13%) | 3 (100%) | 1 (17%) |
| Prescription dose (Gy)/fraction | |||
| 18/1 | 26 (90%) | 0 (0%) | 0 (0%) |
| 24-60/3 | 10 (34%) | 1 (33%) | 4 (67%) |
| 28-48/4 | 11 (38%) | 2 (67%) | 2 (33%) |
| 40-50/5 | 5 (17%) | 0 (0%) | 0 (0%) |
| BED10Gy (Gy) | 79.6 (43.2–132) | 47.6 (43.2–47.6) | 43.2 (43.2–47.6) |
MUO, metastasis of unknown origin; PET, positron emission tomography; BED10Gy, biologically equivalent dose using an α/β of 10 Gy in the linear quadratic model.
a
Others include hepatocellular carcinoma, renal cell carcinoma, small cell lung cancer, rectal cancer, gastric cancer, cervical cancer, Ewing’s sarcoma, Melanoma, and metastasis of unknown origin.